N B Leighl

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy
    Raymond Ng
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Lung Cancer 61:262-5. 2008
  2. ncbi Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics
    Leora Horn
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Drugs Aging 24:411-28. 2007
  3. ncbi Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, Natio
    Raymond Ng
    Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2256-61. 2007
  4. ncbi Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer
    Kimberly S Chiew
    Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Health Expect 11:35-45. 2008
  5. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009
  6. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008
  7. doi Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)
    Natasha B Leighl
    Princess Margaret Hospital, Toronto, Canada
    J Thorac Oncol 5:1970-6. 2010
  8. ncbi A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B Leighl
    Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Breast Cancer Res Treat 108:87-92. 2008
  9. pmc Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital, 5th Floor Room 105, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 104:413-8. 2011
  10. ncbi Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006

Detail Information

Publications30

  1. ncbi Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy
    Raymond Ng
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Lung Cancer 61:262-5. 2008
    ..Here we explore the outcomes of these agents' uses in clinical practice...
  2. ncbi Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics
    Leora Horn
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Drugs Aging 24:411-28. 2007
    ..The improvements observed in patients' QOL and the cost effectiveness of docetaxel make it a very reasonable choice in older patients with good performance status and advanced disease who are candidates for chemotherapy...
  3. ncbi Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, Natio
    Raymond Ng
    Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2256-61. 2007
    ..This cost-effectiveness analysis of adjuvant chemotherapy from the perspective of Canada's public health care system was undertaken based on the JBR.10 study population...
  4. ncbi Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer
    Kimberly S Chiew
    Department of Medical Oncology and Hematology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Health Expect 11:35-45. 2008
    ..We report the development and evaluation of a decision aid (DA) designed to assist patients facing this treatment decision...
  5. pmc A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium
    Natasha B Leighl
    Princess Margaret Hospital Phase 2 Consortium, Ontario, Canada
    J Thorac Oncol 4:1163-9. 2009
    ..This study determined the recommended phase II dose (RP2D) of docetaxel plus GTI-2040, toxicity, and response rate in advanced non-small cell lung cancer (NSCLC)...
  6. pmc Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    Br J Cancer 98:1769-73. 2008
    ..The DA for advanced NSCLC is feasible, acceptable to patients and improves understanding of advanced NSCLC without increasing patient anxiety...
  7. doi Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL)
    Natasha B Leighl
    Princess Margaret Hospital, Toronto, Canada
    J Thorac Oncol 5:1970-6. 2010
    ..A retrospective subgroup analysis was performed to assess the efficacy and safety of bevacizumab-based therapy in elderly patients aged 65 years or older in AVAiL...
  8. ncbi A Phase 2 study of perifosine in advanced or metastatic breast cancer
    Natasha B Leighl
    Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, ON, Canada
    Breast Cancer Res Treat 108:87-92. 2008
    ..Perifosine, an oral alkylphospholipid structurally related to miltefosine, has marked activity against breast cancer cell lines and xenograft models, with broad spectrum cellular effects...
  9. pmc Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
    N B Leighl
    Division of Medical Oncology, Princess Margaret Hospital, 5th Floor Room 105, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 104:413-8. 2011
    ..Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of concurrent bevacizumab and TA in three large placebo-controlled clinical studies...
  10. ncbi Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    Natasha B Leighl
    Princess Margaret Hospital University of Toronto, Department of Medicine, 5 222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Lung Cancer 52:327-32. 2006
    ..Response rates for second-line chemotherapy are 15-25%, with a median survival of 5 months. Caelyx, a pegylated liposomal formulation of doxorubicin, may be better tolerated and has activity in SCLC...
  11. ncbi A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer
    Natasha B Leighl
    Department of Medicine, Faculty of Medicine, Princess Margaret Hospital University Health Network, University of Toronto, 5 222 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Lung Cancer 51:115-21. 2006
    ..We evaluated patient utility through willingness-to-pay (WTP) for these agents in the treatment of advanced NSCLC in Canada...
  12. ncbi Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18
    Natasha B Leighl
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada
    J Clin Oncol 23:2831-9. 2005
    ..In early phase studies, BMS- 275291 was not associated with dose-limiting joint toxicity seen with other MMPIs...
  13. doi Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy
    Natasha B Leighl
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:2077-84. 2011
    ..We examined its impact on patient understanding, treatment decisions, decisional conflict, decision making, consultation satisfaction, anxiety, and quality of life by using a randomized trial design...
  14. ncbi Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 22:1759-62. 2004
  15. ncbi A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    Clin Lung Cancer 5:107-12. 2003
    ..2 mg/m2 I.V. every 21 days. Antitumor activity was seen at all dose levels. This combination is well tolerated and has evidence of antitumor activity. A phase II evaluation is ongoing...
  16. doi Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials
    Timothy R Asmis
    National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
    J Clin Oncol 26:54-9. 2008
    ..The main objective was to determine if age and/or the burden of chronic medical conditions (comorbidity) are independent predictors of survival, treatment delivery, and toxicity...
  17. doi Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer
    Penelope A Bradbury
    NCIC Clinical Trials Group, Kingston, ON, Canada
    J Natl Cancer Inst 102:298-306. 2010
    ..We undertook an economic analysis of erlotinib treatment in this trial and explored different molecular and clinical predictors of outcome to determine the cost-effectiveness of treating various populations with erlotinib...
  18. doi Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer
    Humberto Lara-Guerra
    University Ave, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 27:6229-36. 2009
    ..Their role in early-stage NSCLC has not been established. Our purpose was to explore the use of preoperative gefitinib in clinical stage I NSCLC to assess tumor response, toxicity, and clinical and molecular predictors of response...
  19. doi An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    A M Horgan
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    Ann Oncol 22:1805-11. 2011
    ..Gefitinib had a better toxicity profile and greater improvements in quality of life (QoL). We undertook a cost-consequence analysis to estimate the direct medical costs of gefitinib compared with docetaxel...
  20. ncbi A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung
    Natasha B Leighl
    Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Canada
    J Thorac Oncol 5:1054-9. 2010
    ..This study evaluated the efficacy and safety of intravenous aflibercept in patients with platinum- and erlotinib-resistant lung adenocarcinoma...
  21. pmc A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Hospital, University Health Network, University of Toronto, 610 University Avenue, 5 700, Toronto, Ontario M5G 2M9, Canada
    Br J Cancer 107:604-11. 2012
    ..To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin...
  22. pmc Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial
    Raymond W Jang
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 27:4268-73. 2009
    ..To aid in treatment decision making, quality-adjusted survival estimates of the JBR.10 trial were derived using a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis...
  23. ncbi Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer
    Natasha B Leighl
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 20:1344-52. 2002
    ..To determine the cost-effectiveness (CE) of second-line docetaxel compared with best supportive care (BSC) in the TAX 317 trial, a randomized clinical trial of second-line chemotherapy in non-small-cell lung cancer...
  24. ncbi Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
    Lisa K Hicks
    Keenan Research Center, Li Ka Shing Knowledge Institute of St Michael s Hospital, Toronto, Ontario, Canada
    Cancer 115:5516-25. 2009
    ..However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored...
  25. ncbi Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer
    Antonio L Visbal
    Department of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, ON, Canada
    Chest 128:2933-43. 2005
    ..10 trial (5-year survival rate, 15%; risk reduction for recurrence, 40%). Thus, there is compelling evidence to now recommend adjuvant platinum-based combination chemotherapy for patients after resection of early-stage NSCLC...
  26. pmc A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium
    Sara K Taylor
    5 105 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    Oncologist 15:810-8. 2010
    ..We evaluated the activity of single-agent pazopanib in recurrent or metastatic breast cancer (MBC)...
  27. doi Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma
    Winson Y Cheung
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario
    Clin Lung Cancer 10:187-92. 2009
    ..Knowledge of current practice patterns and outcomes could help to inform future research...
  28. ncbi Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
    Farrah Kassam
    Division of Medical Oncology, Princess Margaret Hospital University Health Network, University of Toronto, Ontario, Canada
    J Thorac Oncol 2:39-43. 2007
    ..This study examines whether referral patterns for adjuvant therapy in NSCLC have changed since the presentation of confirmatory trials...
  29. doi Factors contributing to adjuvant therapy decisions
    Kathryn L Howe
    J Thorac Oncol 3:195-6. 2008
  30. ncbi Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
    Giannicola D'Addario
    Kantonsspital St Gallen, Departement Innere Medizin, Fachbereich Onkologie Haematologie, Rorschacherstrasse 95, 9007 St Gallen, Switzerland
    J Clin Oncol 23:2926-36. 2005
    ..This meta-analysis was performed to compare the activity, efficacy and toxicity of platinum-based versus non-platinum-based chemotherapy in patients with advanced non-small-cell lung cancer...